Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nuclear Transmutation03:20

Nuclear Transmutation

12.9K
Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed...
12.9K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

853
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
853

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Veno-Arterial Carbon Dioxide Gap Fails to Detect Renal Medulla Microcirculatory Changes in a Large Animal Model of Sepsis-Associated Acute Kidney Injury.

Shock (Augusta, Ga.)·2026
Same author

Biodistribution of <sup>161</sup>Tb- or <sup>177</sup>Lu-labeled immunoconjugate in comparison with its potential metallic radioactive degradation products and contaminants.

Nuclear medicine and biology·2026
Same author

In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with <sup>225</sup>Ac.

EJNMMI radiopharmacy and chemistry·2025
Same author

Preparation and Characterization of an Engineered FGF1 Conjugated to <sup>161</sup>Tb for Targeting of FGFRs.

ACS omega·2025
Same author

Renal mitochondria response to sepsis: a sequential biopsy evaluation of experimental porcine model.

Intensive care medicine experimental·2025
Same author

Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177.

Nuclear medicine and biology·2025

Related Experiment Video

Updated: May 5, 2026

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh
10:42

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh

Published on: May 3, 2019

8.5K

Practical Aspects of 161Tb Production.

Marie Skálová1, Tereza Janská1, Matěj Štíbr1

  • 1Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7/78, 110 00 Prague, Czech Republic.

Pharmaceuticals (Basel, Switzerland)
|May 4, 2026
PubMed
Summary

Terbium-161 (Tb-161), a promising theranostic radionuclide, can be prepared in high quality and quantity for preclinical and clinical studies. This study details the reproducible production of no-carrier-added Tb-161 using enriched gadolinium targets and cation exchange chromatography.

Keywords:
160Gd161Tbgadolinium-160productionseparationterbium-161

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.2K

Related Experiment Videos

Last Updated: May 5, 2026

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh
10:42

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh

Published on: May 3, 2019

8.5K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.2K

Area of Science:

  • Nuclear chemistry and radiopharmaceutical production
  • Theranostic radionuclide development

Background:

  • Terbium-161 (Tb-161) is a promising theranostic radionuclide with favorable decay characteristics for targeted therapy.
  • Its chemical similarity to Lutetium-177 (Lu-177) positions it as a potential alternative for clinical applications.
  • Tb-161 emits conversion and Auger electrons, enhancing localized therapeutic effects.

Purpose of the Study:

  • To describe the preparation of no-carrier-added Terbium-161 (Tb-161) suitable for preclinical and early clinical studies.
  • To provide practical insights and address challenges in Tb-161 production and purification.
  • To assess the quality and specific activity of the produced Tb-161 for radiopharmaceutical development.

Main Methods:

  • Neutron irradiation of highly enriched Gadolinium-160 (Gd-160) targets.
  • Separation and purification of Tb-161 using cation exchange chromatography (Dowex 50 W × 8).
  • Characterization using gamma-ray spectrometry and ICP-MS for purity and specific activity determination; DOTA labeling assay performed.

Main Results:

  • Production of 1.3-23.7 GBq of Tb-161 from enriched Gd-160 targets.
  • High separation yields (85-99%) and activities (9.9-22.1 GBq) achieved.
  • Highest specific activity of 4.1 GBq/μg (of Tb) obtained; successful DOTA radiolabeling demonstrated.

Conclusions:

  • Reproducible laboratory-scale production of no-carrier-added Tb-161 is feasible using enriched Gd-160 targets and cation exchange chromatography.
  • The method yields significant activity levels suitable for preclinical and clinical investigations.
  • Practical aspects of lanthanoid separation are highlighted, offering valuable insights for radiochemists.